Where can I learn more about this study?
You can find more information about this study on the websites listed below. When a full report
of the study results is available, it can also be found here.
X www.clinicaltrials.gov Once you are on the website, type “NCT03330847”
into the search box and click “Search”.
X www.clinicaltrialsregister.eu Once you are on the website, click “Home and Search”,
then type “2017-002361-22” in the search box and click “Search”.
X www.AstraZenecaClinicalTrials.com Once you are on the website, type “D5336C00001”
into the search box, and click “Find a Study”.
Full Study Title: A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety
and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus
Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients
Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including
BRCA1/2)
AstraZeneca Protocol Number: D5336C00001
National Clinical Trials Number: NCT03330847
EudraCT Number: 2017-002361-22
AstraZeneca sponsored this study and has its headquarters in Cambridge, UK.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you
Clinical study participants belong to a large community of people who take part in
clinical research around the world. They help researchers answer important
health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization focused on
educating and informing the public about clinical research participation. CISCRP is not involved in recruiting participants
for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0 2022_03_24
16 | Clinical Study Results